Cargando…
The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing
Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acut...
Autores principales: | Dunbar, Hazel, Weiss, Daniel J, Rolandsson Enes, Sara, Laffey, John G, English, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616504/ https://www.ncbi.nlm.nih.gov/pubmed/34831203 http://dx.doi.org/10.3390/cells10112982 |
Ejemplares similares
-
MSCs interaction with the host lung microenvironment: An overlooked aspect?
por: Weiss, Daniel J., et al.
Publicado: (2022) -
Quantitative proteomic characterization of lung-MSC and bone marrow-MSC using DIA-mass spectrometry
por: Rolandsson Enes, Sara, et al.
Publicado: (2017) -
MSC from fetal and adult lungs possess lung-specific properties compared to bone marrow-derived MSC
por: Rolandsson Enes, Sara, et al.
Publicado: (2016) -
Research Progress on Strategies that can Enhance the Therapeutic Benefits of Mesenchymal Stromal Cells in Respiratory Diseases With a Specific Focus on Acute Respiratory Distress Syndrome and Other Inflammatory Lung Diseases
por: Rolandsson Enes, Sara, et al.
Publicado: (2021) -
Bioartificial lungs based on de- and recellularisation approaches: a historical perspective
por: Rolandsson Enes, Sara, et al.
Publicado: (2020)